Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin

Documenti analoghi

• Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
  di: Matsubayashi, Yasuhiro, et al.
  Pubblicazione: (2021)
• Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
  di: Nunoi, Kiyohide, et al.
  Pubblicazione: (2019)
• Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
  di: Nunoi, Kiyohide, et al.
  Pubblicazione: (2018)
• Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
  di: Tobe, Kazuyuki, et al.
  Pubblicazione: (2017)
• Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss
  di: Sato, Yuichi, et al.
  Pubblicazione: (2019)